AVALIAÇÃO DE PARÂMETROS LABORATORIAIS, PROTEÍNA C REATIVA E MIELOPEROXIDASE EM INDIVÍDUOS INFECTADOS PELO VÍRUS DA IMUNODEFICIÊNCIA HUMANA

• Ano de defesa: 2011
• Autor(a) principal: Borato, Danielle Cristyane Kalva
• Orientador(a): Vellosa, José Carlos Rebuglio
• Banca de defesa: Beu, Celia Cristina Leme , Khalil, Najeh Maissar
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: UNIVERSIDADE ESTADUAL DE PONTA GROSSA
• Programa de Pós-Graduação: Programa de Pós Graduação Ciências Farmacêuticas
• Departamento: Farmacos, Medicamentos e Biociências Aplicadas à Farmácia
• País: BR
• Palavras-chave em Português: risco cardíaco; HIV; mieloperoxidase
• Palavras-chave em Inglês: cardiac risk; HIV; myeloperoxidase
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: http://tede2.uepg.br/jspui/handle/prefix/101

Atherosclerotic cardiovascular disease has become an important cause of morbidity and mortality among individuals with human immunodeficiency virus (HIV). Currently, most of these patients have access to antiretroviral drugs, which has decreasing the risk for AIDS and increasing life expectancy. Therefore, it is necessary a better monitoring of traditional cardiovascular risk factors, whose changes are often more common in individuals with HIV infection. It is considered important the laboratorial evaluation in patients infected with HIV, with or without development of Acquired Immunodeficiency Syndrome (AIDS) and the establishment of preventive health policies, through the monitoring of mortality and its risk factors. So, there is the necessity to set new trends in laboratory monitoring in patients infected with HIV, such as percentage of CD4+ T cells and early and sensitive biochemical indicators for the risk of developing cardiovascular disease, in order to diagnose life-threatening conditions of the individual, thus increasing the chance of success of treatments needed. Currently, there is growing interest in myeloperoxidase (MPO; 1.11.1.7) as a marker of cardiac risk because of the possibility of performing with high serum levels occurring in the biomolecules that are currently used for this purpose, such as ultra-sensitive C-reactive protein (hs-CRP). This study aimed to assess the levels of MPO levels in HIV-infected individuals, as a possible biomarker for early indication of cardiac risk, together with different laboratory tests for immune monitoring and evaluation of these patients. The results indicated, among others, differences in the percentages of CD4 + T lymphocytes obtained by different methodologies, which could cause conflict in clinical decisions related to treatment and care of people infected with HIV. In addition, there were significant differences in the values of ultrasensitive C-reactive protein (hs-CRP) and serum myeloperoxidase, suggesting their application as laboratory markers with predictive value for cardiovascular events in HIV-infected patients.